

RNS Number : 6177G
EKF Diagnostics Holdings PLC
08 May 2014

**EKF Diagnostics Holdings plc
("EKF", the "Company")**

Director / PDMR Shareholding

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care, central laboratory and molecular diagnostics business, announces that Directors of the Company have today made the following share purchases:

Director	No. of ordinary shares purchased	Purchase price	Total shareholding before purchase	Total shareholding following purchase	Percentage of issued share capital
Julian Baines, Chief Executive Officer	100,000	25.07p	1,621,955	1,721,955	0.41%
David Evans, Executive Chairman	100,000	25.07p	1,605,753	1,705,753	0.40%
Paul Foulger, Chief Financial Officer	50,000	25.07p	3,438,589	3,488,589	0.83%
Richard Evans, Chief Operating Officer	25,000	25.07p	153,842	178,842	0.04%
Adam Reynolds, Non-Executive Director	25,000	25.07p	3,204,724	3,229,724	0.77%
Kevin Wilson, Non-Executive Director	50,000	25.07p	617,846	667,846	0.16%

Enquiries:

EKF Diagnostics Holdings plc
Julian Baines, CEO

Tel: 029 2071 0570
Mob: 07788 420 859

Canaccord Genuity Limited
Nominated Adviser/Corporate Broking
Lucy Tilley /Julian Feneley /Henry Fitzgerald-O'Connor /Chris Connors

Tel: 020 7523 8350

Walbrook PR Limited
Paul McManus

Tel: 020 7933 8780
Mob: 07980 541 893 or
paul.mcmanus@walbrookpr.com
Mob: 07584 391 303 or
lianne.cawthorne@walbrookpr.com

Lianne Cawthorne

About EKF Diagnostics Holdings plc - www.ekfdiagnostics.com

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient

Diagnostics Limited (acquired in September 2010), Argutus Medical Limited (acquired in December 2010) and Stanbio Laboratory L.P. (acquired in June 2011). In 2013 EKF established a new subsidiary, EKF Molecular Diagnostics Ltd, to focus on molecular and companion diagnostics and acquired 360 Genomics Ltd, a business that owns diagnostics technologies for cancer gene detection.

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focussing on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In March 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.

In March 2014, EKF acquired Separation Technology, Inc., a Florida based manufacturer of in vitro diagnostics devices for the haematology testing market for a total consideration of \$4.0m (c.£2.4m). In April 2014, EKF completed the acquisitions of Selah Genomics Inc., a US based developer of molecular diagnostics for personalised medicine and DiaSpect Medical AB., a Swedish based manufacturer of point-of-care haemoglobin analysers.

This information is provided by RNS
The company news service from the London Stock Exchange

END

RDSBDGDUIGGBGSI admin Director/PDMR Shareholding 21678870 A Thu, 05/08/2014 - 13:10
Directors' Dealings EKF